Who are Basiliximab, Tacrolimus, MMF, Prednisolon's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ponticelli Regimen, Twice daily immunosuppression regimen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/basiliximab-tacrolimus-mmf-prednisolon.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Basiliximab, Tacrolimus, MMF, Prednisolon — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Basiliximab, Tacrolimus, MMF, Prednisolon (Basiliximab, Tacrolimus, MMF, Prednisolon) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive combination regimen. Area: Immunology / Transplantation.

marketed Immunosuppressive combination regimen IL-2 receptor (basiliximab), calcineurin (tacrolimus), IMPDH (MMF), glucocorticoid receptor (prednisolone) Immunology / Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

Basiliximab, Tacrolimus, MMF, Prednisolon (Basiliximab, Tacrolimus, MMF, Prednisolon) — University Hospital Freiburg. This is a multi-drug immunosuppressive regimen that blocks T-cell activation and proliferation to prevent organ rejection after transplantation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Basiliximab, Tacrolimus, MMF, Prednisolon TARGET	Basiliximab, Tacrolimus, MMF, Prednisolon	University Hospital Freiburg	marketed	Immunosuppressive combination regimen	IL-2 receptor (basiliximab), calcineurin (tacrolimus), IMPDH (MMF), glucocorticoid receptor (prednisolone)
Ponticelli Regimen	Ponticelli Regimen	Beijing Friendship Hospital	marketed	Immunosuppressive combination regimen
Twice daily immunosuppression regimen	Twice daily immunosuppression regimen	Washington University School of Medicine	marketed	Immunosuppressive combination regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive combination regimen class)

Beijing Friendship Hospital · 1 drug in this class
University Hospital Freiburg · 1 drug in this class
Washington University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Basiliximab, Tacrolimus, MMF, Prednisolon — Competitive Intelligence Brief. https://druglandscape.com/ci/basiliximab-tacrolimus-mmf-prednisolon. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab